Peter C. Albertsen

UConn Health — United States

Medicine · Health Sciences

71h-index22.6kcitations532works11.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Diagnosis and Treatment(280), Prostate Cancer Treatment and Research(239), Bladder and Urothelial Cancer Treatments(72), Health Systems, Economic Evaluations, Quality of Life(52), Healthcare Policy and Management(50)

Publications517 total

The contemporary management of prostate cancer
CA A Cancer Journal for Clinicians·2025· 13 citedOpen Access
Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer
European Urology·2025
IP21-16 SOFTWARE VERSUS COGNITIVE FUSION FOR THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: DOES ‘LESION DENSITY’ MATTER?
The Journal of Urology·2025
Michael Droller: Teacher, mentor, confidant and friend
Urologic Oncology Seminars and Original Investigations·2025
Screening for homologous recombination genes
Prostate Cancer and Prostatic Diseases·2024· 1 citedOpen Access
Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu’s Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20–6
European Urology·2024
Cost-effective Prostate-specific Antigen Screening: Who Do We Screen and What Treatments Do We Offer?
European Urology·2024
MP49-18 DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING COGNITIVE VERSUS SOFTWARE-BASED MRI-TARGETING DURING TRANSPERINEAL PROSTATE BIOPSY: A MULTI-INSTITUTIONAL ANALYSIS
The Journal of Urology·2024
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
JAMA·2024· 81 citedOpen Access
Response to ‘Endpoint and control group in prostate cancer screening research: public health basics’
British Journal of Urology·2024
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer
European Urology·2024· 45 citedOpen Access
Screening and active surveillance in prostate cancer: the dilemma continues
British Journal of Urology·2024Open Access
When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen
European Urology·2023
Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge
British Journal of Urology·2023· 13 citedOpen Access
Can PSA testing become appropriate public health policy?
BMJ Oncology·2023Open Access
The performance of prostate specific antigen (PSA) testing in the population based NPCC cohort.
Journal of Clinical Oncology·2023
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium
European Urology·2023· 10 citedOpen Access
Editorial Board
British Journal of Urology·2023Open Access
Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy
PLoS ONE·2022· 4 citedOpen Access
Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues
European Urology·2022· 4 cited
page 1 of 26Next →

Frequent Co-authors

Janet L. Stanford(14), David F. Penson(10), Ann S. Hamilton(10), Arnold L. Potosky(10), Richard M. Hoffman(9), Robert A. Stephenson(8), Frank D. Gilliland(7), Michael J. Barry(5), J. William Eley(5), Peter R. Carroll(5), Ziding Feng(4), Linda C. Harlan(4), Laurence Klotz(4), Oliver Sartor(4), Lauri Miller(4), Donald L. Kreutzer(4), H. Ballentine Carter(3), Stephen J. Freedland(3), Kirsten L. Greene(3), Anthony L. Zietman(3)